BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BI 3034701 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of BI 3034701\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07837648-153@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:BI 3034701: Phase 1 readout est. (NCT07837648)
DESCRIPTION:BI 3034701\, phase 1.\nStudy: A Study to Test How Much BI 30347
 01 Gets Into the Blood in Healthy People When Given in Two Different Ways\
 nEstimated primary completion: 15 December 2026. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/bi-3034701#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07837648
URL:https://assetmemo.bio/drug/bi-3034701#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07693231-153@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20261222
DTEND;VALUE=DATE:20261223
SUMMARY:BI 3034701: Phase 1 readout est. (NCT07693231)
DESCRIPTION:BI 3034701\, phase 1\, Obesity.\nStudy: A Study to Test How Wel
 l Different Doses of BI 3034701 Are Tolerated by Japanese Healthy People a
 nd Japanese People With Obesity or Overweight\nEstimated primary completio
 n: 22 December 2026. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 bi-3034701#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07693231
URL:https://assetmemo.bio/drug/bi-3034701#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07754474-153@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20270621
DTEND;VALUE=DATE:20270622
SUMMARY:BI 3034701: Phase 1 readout est. (NCT07754474)
DESCRIPTION:BI 3034701\, phase 1\, Obesity.\nStudy: A Study to Test How Wel
 l Different and Multiple Doses of BI 3034701 Are Tolerated in People Livin
 g With Overweight or Obesity\nEstimated primary completion: 21 June 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/bi-3034701#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07754474
URL:https://assetmemo.bio/drug/bi-3034701#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07662122-153@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20270626
DTEND;VALUE=DATE:20270627
SUMMARY:BI 3034701: Phase 2 readout est. (NCT07662122)
DESCRIPTION:BI 3034701\, phase 2\, Obesity.\nStudy: A Study to Test Whether
  BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweigh
 t\nEstimated primary completion: 26 June 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/bi-3034701#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07662122
URL:https://assetmemo.bio/drug/bi-3034701#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
